Kathryn Atkins, Author at Oncotarget

Oncotarget News

Oncotarget is Again on MEDLINE

October 27, 2022

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed.The United... read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.”BUFFALO, NY- October 25, 2022 – A new... read more

Oncotarget

Oncotarget | Platelet-derived Growth Factor (PDGF) Cross-Signaling Via Non-Corresponding Receptors Indicates Bypassed Signaling in Colorectal Cancer

October 20, 2022

The present study analyzed PDGFR and VEGFR expression in primary colon cancer tissues and CRC cell lines in order to better define their expression profiles. Furthermore, we analyzed putative PDGF... read more

Oncotarget

Oncotarget | Effectiveness of Radiotherapy for Local Control in T3N0 Rectal Cancer Managed With Total Mesorectal Excision: A Meta-analysis

October 13, 2022

To the best of our knowledge, this is the first study to date to perform a systematic review or meta-analysis regarding the benefit of radiotherapy specific to the T3N0 rectal... read more

Oncotarget

Oncotarget | In vitro Chemotherapy-associated Muscle Toxicity Attenuated With Nutritional Support, While Treatment Efficacy Retained

October 11, 2022

Our in vitro study demonstrates the importance of specialized nutritional support and combining multiple nutrients to reach maximum effect to attenuate chemotherapy-associated muscle toxicity of skeletal muscle in cancer patients.”... read more

Oncotarget

Oncotarget | Genomic Alterations Predictive of Poor Clinical Outcomes in Pan-cancer

October 4, 2022

PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on September 28, 2022, entitled, “Genomic alterations predictive of poor clinical outcomes in pan-cancer.”BUFFALO, NY- October 4,... read more

Oncotarget

Oncotarget | Site of Analysis Matters – Ongoing Complete Response to Nivolumab in Patient With HIV/HPV Related Metastatic Anal Cancer and MLH1 Mutation

September 29, 2022

This case report represents an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB), and an ongoing response to Nivolumab.”BUFFALO,... read more

Oncotarget

Oncotarget | Targeting Krebs-cycle-deficient RCC with Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemotherapy

September 20, 2022

In this study, we sought to examine the activity of combined TMZ and PARPi in Krebs-cycle-deficient renal cancer models.”BUFFALO, NY- September 20, 2022 – A new research paper was published... read more

Oncotarget

Oncotarget | An ABC Transporter as Potential Target Against SHH-Medulloblastoma: From Benchtop to Bedside

September 15, 2022

The discovery of novel modulators of the SHH pathway to advance SHH-MB treatment is greatly needed.”BUFFALO, NY- September 15, 2022 – A new editorial paper was published in Oncotarget on... read more

Oncotarget

Oncotarget | Targeted Elastin-like Polypeptide Fusion Protein for Near-infrared Imaging of Human and Canine Urothelial Carcinoma

September 8, 2022

We have developed a peptide-based NIR probe, Cy5.5-N24-EGF, that shows high EGFR-specific binding specificity in canine and human UC in vitro and ex vivo.”BUFFALO, NY- September 8, 2022 –... read more